Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response - Wikidata - awgldk - TriplyDB

Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response

Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response

http://www.wikidata.org/entity/Q35297067

about

Lipid-lowering efficacy of atorvastatin Lipid lowering efficacy of atorvastatin Evaluating the accuracy of AIM panels at quantifying genome ancestry Differentiation of African components of ancestry to stratify groups in a case-control study of a Brazilian urban population.Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans.Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2 Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Seventeen years of statin pharmacogenetics: a systematic review.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics.

P2860

Q24187301-567EB08F-3ACB-47D0-AF38-D1136D023946 Q24202363-0BAE2608-32FC-4263-B9D1-ECB1E45CA7D0 Q33911891-919004AE-4EB9-49F5-8D07-0787B90333D1 Q36041632-C272FB0D-3BE7-4A82-A4BF-84F88EAECF18 Q36111214-A9E763D9-F978-4753-9C99-613BCBDD5975 Q36184009-74A4D701-49A5-4F94-8BBB-1CEFE21322C2 Q36623470-5C74C68E-8B59-4A41-A754-FD62DF2B15E5 Q36998199-9681F6E2-6214-497F-BCF6-D7BA3C042064 Q37207831-5A9DC9DB-16E8-4DF2-9FC5-8846E7B1E1A9 Q37422685-87E1EF04-35FC-4058-9878-B6C1E3D3FB3A Q38003174-8A633A3B-4820-43A2-AAD3-4A505B60DD5D Q38670109-AB199E2A-C132-48EE-8ECA-2F90CF57031A Q38888369-8AC771D2-FE64-454B-80C2-B10A2E4EB393 Q39448926-578A6324-8AC6-4041-84EB-535BBDF61B5B Q39683666-9A35458C-64B5-4181-AE92-969B185BF432

P2860

Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response

http://www.wikidata.org/entity/Q35297067

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Pharmacogenetics of OATP trans ...... ncreased atorvastatin response

@ast

Pharmacogenetics of OATP trans ...... ncreased atorvastatin response

@en

type

label

Pharmacogenetics of OATP trans ...... ncreased atorvastatin response

@ast

Pharmacogenetics of OATP trans ...... ncreased atorvastatin response

@en

prefLabel

Pharmacogenetics of OATP trans ...... ncreased atorvastatin response

@ast

Pharmacogenetics of OATP trans ...... ncreased atorvastatin response

@en

P1433

Q35297067-4CC71AB3-17AE-4FB8-A839-7C77685A4CD1

P1476

Q35297067-33448E11-CDEF-437F-8AC5-862414745589

P2093

Q35297067-25F7F4C9-C3A4-4909-AC75-7C79816D5D49

Q35297067-36E756B5-1EE9-4A0E-BD17-DC9C7ADB14FA

Q35297067-4462FB5E-90BE-48AE-A5CA-64F948B83CDA

Q35297067-4B4EB9DA-C694-4904-A770-61EAA96C7983

Q35297067-554D8499-8124-46C9-81C6-849E4184C2F2

Q35297067-5553A68F-EB39-4070-A2AD-21DD3EDC1FF1

Q35297067-83811045-AFED-4CDA-AFCE-32BCB3A553F8

Q35297067-83897F13-228D-41AD-8EA7-EC47CCC37238

Q35297067-9163DDA9-4E3A-4A70-A951-36B809183E34

Q35297067-96D3EF68-307D-4E88-804C-22F33EA9C453

P2860

Q35297067-14577BD0-D5B8-404D-A2CC-4556E9A7AA98

Q35297067-19EE6D21-46D3-4DA8-B888-161A7FC095FD

Q35297067-1A82AB7F-4EFE-47E1-9E71-7DB7994DBD92

Q35297067-283ED7BB-2496-45C7-932F-64D248A58250

Q35297067-31407D66-34AE-4BB9-AF1B-152520768F48

Q35297067-371A20C3-A5D3-4073-B896-A8E019C1B0EF

Q35297067-379BD054-0569-4B5A-956F-9632DD14C6DF

Q35297067-474241F5-12E9-421E-9BC2-D8D3B329B0E8

Q35297067-49F35627-D092-43E5-BB7C-93DCB18DFAD1

Q35297067-52CF067A-56A6-4839-B236-4B128BCC8333

P304

Q35297067-C06A3512-3763-495D-9991-8917ADC57DD1

P31

Q35297067-A194C22E-58DA-4062-A928-9224D3F1F23B

P356

Q35297067-D0F3C2E1-F210-4244-ADF0-A4DF8DE76AB9

P407

Q35297067-4D0A7F25-E58A-4280-A340-09850FB9950F

P433

Q35297067-B5517B59-74A9-4C09-B513-06DBCDB1A574

P478

Q35297067-D2810248-DBB6-4D50-8938-DA7873D8A437

P50

Q35297067-05B0C5D5-58BE-460A-AA7D-AA1A4D3BDE08

Q35297067-8403A87C-1221-429B-9307-A4B139AE275C

Q35297067-86BB8CE8-5BE5-4998-B339-53F2AC7C2A38

Q35297067-BAAB0459-807C-43A4-BBF6-0AAEC606B514

Q35297067-CB6C143A-75EA-4FD4-879F-868C60725895

Q35297067-D94FA3C2-BA47-41AE-83B1-64591B83B68C

P577

Q35297067-9108955E-C594-4E0B-BAC0-72BF10DA9F8B

P5875

Q35297067-E2014BB3-4B7D-4231-BDD0-F6C1E3A7FED0

P698

Q35297067-BE2F3770-2218-41E8-BD22-9644D3889EC6

P932

Q35297067-D58B7816-61E2-4171-B62D-286F07897DB8

P356

P1433

International Journal of Molecular Sciences

P1476

Pharmacogenetics of OATP trans ...... ncreased atorvastatin response

@en

P2093

Ana Freire

http://www.w3.org/2001/XMLSchema#string

Andre A Faludi

http://www.w3.org/2001/XMLSchema#string

Egidio L Dorea

http://www.w3.org/2001/XMLSchema#string

Fabiana D V Genvigir

http://www.w3.org/2001/XMLSchema#string

Liliana Porras-Hurtado

http://www.w3.org/2001/XMLSchema#string

Manuel Fondevila

http://www.w3.org/2001/XMLSchema#string

Marcelo C Bertolami

http://www.w3.org/2001/XMLSchema#string

Marcia M S Bernik

http://www.w3.org/2001/XMLSchema#string

Maria Alice V Willrich

http://www.w3.org/2001/XMLSchema#string

Maria V Lareu

http://www.w3.org/2001/XMLSchema#string

P2860

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

Human skeletal muscle drug transporters determine local exposure and toxicity of statins

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

SLCO1B1 variants and statin-induced myopathy--a genomewide study

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

Update on statins: 2003.

SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.

DNA tests probe the genomic ancestry of Brazilians.

P304

5815-5827

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/IJMS12095815

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Angel Carracedo

Alice Cristina Rodrigues

Christopher Phillips

André D. Luchessi

P577

2011-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51733328

http://www.w3.org/2001/XMLSchema#string

P698

22016628

http://www.w3.org/2001/XMLSchema#string

P932

3189752

http://www.w3.org/2001/XMLSchema#string